NEOPLASMS BY HISTOLOGIC TYPE

This study tests capmatinib, a drug already approved for certain lung cancers, in adults with rare cancers that have specific MET gene changes. About 30 people will take part to see if the drug can shrink tumors or stop cancer from growing for at least 24 weeks. The goal is to fi…

This early-stage study tests the safety of a new drug called ziftomenib when combined with standard chemotherapy for people with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. About 171 adults with certain genetic markers (NPM1 m…

This early-stage study tests a new gene therapy called KLN-1010 for people with multiple myeloma that has come back or not responded to treatment. Instead of removing cells and engineering them in a lab, this therapy delivers a gene directly into the body to create cancer-fightin…

This study tests atezolizumab, a drug already approved for some cancers, in people with rare cancers that have high tumor mutational burden (TMB) or microsatellite instability (MSI). About 30 adults and children with these genetic changes will receive the drug to see if their tum…

This study tests a drug called entrectinib in people with rare cancers that have a specific gene change (ROS1 fusion). The drug is already approved for some lung cancers, and researchers want to see if it helps shrink tumors or stop them from growing in other cancer types. About …

This early-phase study tests whether a specially engineered virus called G207 is safe for children whose cerebellar brain tumors have come back or not responded to standard treatments. Up to 24 children aged 3 to 21 will receive the virus directly into the tumor, along with a low…

This study tests a drug called alectinib, already approved for some lung cancers, in people with rare cancers that have a specific genetic change called ALK. About 30 adults, teens, and children with ALK-positive cancers will receive alectinib to see if it shrinks tumors or stops…